about
Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trialEfficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized TrialSodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled TrialY chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in Sudan.Loss of balancing selection in the betaS globin locusPrevalence of latent tuberculosis infection in Sudan: a case-control study comparing interferon-γ release assay and tuberculin skin test.Subtotal laparoscopic cholecystectomy influences the rate of conversion in patients with difficult laparoscopic cholecystectomy: Case seriesPost-kala-azar dermal leishmaniasis.Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.Submicroscopic and multiple plasmodium falciparum infections in pregnant Sudanese womenSurvey of causative agents for acute respiratory infections among patients in Khartoum-State, Sudan, 2010-2011.The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs.Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.Interleukin 10 gene polymorphisms and development of post kala-azar dermal leishmaniasis in a selected sudanese populationTreatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond.Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy.Misdiagnosis and mistreatment of post-kala-azar dermal leishmaniasis.Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan.Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).Aflatoxin M₁ in breast milk of nursing Sudanese mothers.Evaluation of the particle gel diffusion technique for the detection of haemoglobin S in Sudanese patients.High altitude and pre-eclampsia: Adaptation or protection.SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan.Post-kala-azar dermal leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan?Diagnosis of tuberculous lymphadenitis by FNAC, microbiological methods and PCR: a comparative study.Uncommon clinical presentations of cutaneous leishmaniasis in Sudan.Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis.Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan.Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers.Allele frequency and genotype distribution of polymorphisms within disease-related genes is influenced by ethnic population sub-structuring in Sudan.Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1.Etiological Trends and Patterns of Antimicrobial Resistance in Respiratory Infections.Leishmania donovani: genetic diversity of isolates from Sudan characterized by PCR-based RAPD.Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: Does ultraviolet light (UVB) radiation play a role?
P50
Q28538775-281EFC42-567F-4711-8FE3-5C648F1DE9FCQ28554069-D63E4E4E-E075-43BC-A3EC-E21E167E86F8Q28972231-E52E7806-64CF-474D-ACEC-BE8727983E5CQ33284534-C6D434E7-BC5D-4F7D-9459-400F74838467Q33529284-AE4428BF-089F-4AED-8D93-B44F4ACF2EF2Q33643951-43394DE8-BA12-46E2-926B-ECB28CF46824Q33746320-6B30D150-C622-45B6-A09C-2E5CA74304F8Q35057435-E0298022-121C-497D-9CE0-B0414CC9F873Q35163598-0F2AC0B7-2A51-474C-A297-CA57332D60E6Q35913444-68F1FC04-49D1-484F-B1B6-7CDB32C8F144Q37319215-04906FF2-578B-40B4-BD1E-93EE34FF4842Q37372627-DBAB74EE-2017-4540-8217-A4375B28E697Q37588236-FD0F8B4A-DE52-43F0-A42E-6A3D7DA19A69Q38108301-5A0585A3-5CC2-4835-BCEE-394C7146A61BQ40499593-C01A0238-5E1C-472C-8E91-93499A325F23Q41830302-72BAE61C-727C-48C0-B99B-7E3F03043C13Q42541695-A05B60C0-7934-43E9-9463-20E4ADE4D205Q42543877-7A79C923-5A3A-4304-916B-586511119949Q43226918-295AF26F-CA06-4B8C-A9C0-A15106FD518EQ44859021-DA56ABF3-6E6A-4302-A822-FE13C1166FEFQ44884159-7F2A4E64-2F78-476A-B5D2-B99438CCE3D3Q44934751-4E4EAD3E-BD43-430D-A7C3-C8E30D3F0CF0Q46150956-7051FC34-D8A6-4D8A-AB9F-8D623E287673Q46152386-77AB7C33-E0D6-42D2-B833-76AEEB281091Q46176230-DAA50E48-0E80-4CCF-A023-ED3BA3D349F0Q46304833-BF3D7467-AE71-44B5-9EC0-8D0E11538E1CQ46455738-E83F862A-06E2-47F2-BCF0-72B88DBE9BFBQ46649212-14479572-63BD-42AF-BAB7-4E11D9D40F0FQ46760054-FAD7038B-1AB6-48AA-8747-A89FC9FC40A1Q46778727-3512690C-7C29-402C-8413-C37F59A9B3E0Q46792213-DB941254-C2B5-45F6-A6E7-05D882E1E8F9Q46797974-2DCD6528-8164-4036-B26D-DF5955EB583FQ47709127-8682D1E2-7983-4171-9D4E-7703F7B74582Q47898726-60449755-99C3-486A-920A-9D0BAF9619B5Q51902268-C0461040-295B-405C-AB59-D48B296D9BB7Q52952871-81C15D8D-D467-44C0-87B9-309C93333EA7Q54203484-28B60DC8-52CC-4F82-97AA-8AF6887C77EEQ54434900-A3113EB1-980E-48D4-A492-79E21FF364D8Q55106221-D0513604-1C2E-4394-83F8-CB66B0EBA2EDQ57633643-12F5D257-1064-44F8-A3AF-143CD2E765DC
P50
description
researcher
@en
wetenschapper
@nl
name
E A Khalil
@en
E A Khalil
@nl
type
label
E A Khalil
@en
E A Khalil
@nl
prefLabel
E A Khalil
@en
E A Khalil
@nl
P106
P31
P496
0000-0002-5165-6902